Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Hospital-Acquired Infection Diagnostics Market $6.7 Billion by 2031

The global market for hospital-acquired infection diagnostics estimated to reach $6.7 billion by 2031, expanding at a double-digit CAGR of 16.4% over the forecast period, driven by increasing number of drug resistant pathogens such as MRSA, pneumonia caused by viruses, bacteria, or fungi, as well as blood stream and urinary bacteria.

Global Hospital-Acquired Infection Diagnostics Market

Hospital-acquired infections (HAIs) or healthcare-associated infections are nosocomially acquired infections that are not present or incubating at the time of admission to a hospital. These infections include catheter-associated urinary tract infections, central line-associated bloodstream infections, surgical site infections, ventilator-associated pneumonia, hospital-acquired pneumonia, and Clostridium difficile infections. These infections can be contracted from the environment or staff of a healthcare facility.

According to WHO estimates, approximately 15% of all hospitalized patients suffer from these infections. 

  • Nosocomial pathogens include bacteria, viruses and fungal parasites. Bacteria alone cause about 90 percent of these cases.
    • Nosocomial infections accounts for 7% in developed and 10% in developing countries. The mode of infection transfer includes unclean hands, and medical instruments such as catheters, respiratory machines, and other hospital tools.
      • These infections occur worldwide both in developed and developing countries.

The most frequent types of infections include central line-associated bloodstream infections, catheter-associated urinary tract infections, surgical site infections and ventilator-associated pneumonia. 

  • Hospital-acquired infections are diagnosed using a thorough physical examination, blood tests, blood cultures, and special studies include molecular testing, to identify the specific pathogen.
    • HAIs categorized by Centers for Disease Control and Prevention (CDC) include UTI, SSIs (superficial or deep incisional-site infection, organ/space infection), pneumonia, bloodstream infection, bone and joint infection, CNS infection, cardiovascular system infection, ear, eye, nose throat, or mouth infection, GI system infection, lower respiratory system infection (excluding pneumonia), reproductive tract infection, skin and soft tissue infection, and systemic infection.
    • HAI infections include central line-associated bloodstream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI), hospital-acquired Pneumonia (HAP), ventilator-associated Pneumonia (VAP), and Clostridium difficile infections (CDI).
    • The dominant infections (in descending order) include Pneumonia (21.8%), surgical site infections (21.8%), gastrointestinal infections (17.1%), urinary tract infections or UTIs (12.9%), and primary bloodstream infection (9.9%, and include Catheter-associated bloodstream infections). 
    • For the last few decades, hospitals have taken the hospital-acquired infections seriously. Several hospitals have established infection tracking and surveillance systems in place, along with robust prevention strategies to reduce the rate of hospital-acquired infections.

The hospital-acquired infection testing market report estimates the market size ($million 2021 to 2031), market share, growth trends, and forecast (CAGR% 2024 to 2031).

The global market for hospital-acquired infection diagnostics segmented by disease / infection test [blood stream associated infection, methicillin-resistant Staphylococcus aureus infection, hospital-acquired pneumonia, surgical associated infection / surgical site infection, urinary tract infection, others (gastroenteritis, puerperal fever)], and geography.

  • Based on infection tests, the hospital acquired urinary tract infections (UTIs) segment accounted for largest share of the overall market, attributed to rising incidences of infections caused by urinary catheters, and increasing antimicrobial resistance worldwide.
    • The hospital-acquired pneumonia (HAP) segment predicted to register the fastest CAGR during the forecast period, as it is one of the most prevalent nosocomial infections worldwide.
      • Based on the guidelines from both the Infectious Disease Society of America (IDSA) and the American Thoracic Society (ATS), the HAP occurs 48 hours or more after admission to the hospital and did not appear to be incubating at the time of admission. The ventilator-associated pneumonia (VAP) develops more than 48 to 72 hours after endotracheal intubation.
        • Both HAP and VAP are associated with poorer outcomes and significant morbidity and mortality worldwide.

The global market for hospital-acquired infection diagnostics research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

  • Geographically, the North America region dominated the global hospital-acquired disease testing market, followed by the Europe region, owing to rapid adoption of advanced molecular diagnostics methods, well-defined regulatory framework and observation guidelines.
    • On the other hand, the Asia Pacific market anticipated to witness the fastest growth rate in the near future, driven by increasing prevalence of infectious diseases, large number of surgeries, and improving healthcare infrastructure in the region.

The global hospital-acquired disease testing market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in the global hospital-acquired disease diagnostics market and included in this report are Abbott Laboratories, Inc., Becton, Dickinson and Company, bioMérieux S.A., Cepheid, Inc., Eurofins Scientific (Diatherix Laboratories, Inc.), Roche Holding AG (F. Hoffmann-La Roche AG), Hologic, Inc., Meridian Bioscience, Inc., Qiagen NV, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc.

  • Disease / Infection Test
    • Blood Stream Associated Infection
    • Methicillin-resistant Staphylococcus aureus (MRSA) infection
    • Hospital-Acquired Pneumonia (HAP)
    • Surgical Associated Infection / Surgical Site Infection (SSI)
    • Urinary Tract Infection (UTI)
    • Others
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Becton, Dickinson and Company
    • bioMérieux S.A.
    • Cepheid, Inc.
    • Eurofins Scientific (Diatherix Laboratories, Inc.)
    • Roche Holding AG (F. Hoffmann-La Roche AG)
    • Hologic, Inc.
    • Meridian Bioscience, Inc.
    • Qiagen NV
    • Siemens Healthineers AG
    • Thermo Fisher Scientific, Inc. (Life Technologies Corp.)

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/hospital-acquired-disease-testing-market/

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com